CN101193858B - 神经蛋白酶抑制剂及其确定 - Google Patents

神经蛋白酶抑制剂及其确定 Download PDF

Info

Publication number
CN101193858B
CN101193858B CN2006800101171A CN200680010117A CN101193858B CN 101193858 B CN101193858 B CN 101193858B CN 2006800101171 A CN2006800101171 A CN 2006800101171A CN 200680010117 A CN200680010117 A CN 200680010117A CN 101193858 B CN101193858 B CN 101193858B
Authority
CN
China
Prior art keywords
agrin
neuroprotease
neuroproteases
cleavage
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800101171A
Other languages
English (en)
Chinese (zh)
Other versions
CN101193858A (zh
Inventor
P·松德雷杰
S·赫特沃
M·F·博利杰
B·德赖尔
B·孔茨
D·卢谢
R·赖夫
S·萨尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN101193858A publication Critical patent/CN101193858A/zh
Application granted granted Critical
Publication of CN101193858B publication Critical patent/CN101193858B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2006800101171A 2005-03-30 2006-03-29 神经蛋白酶抑制剂及其确定 Expired - Fee Related CN101193858B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102481 2005-03-30
EP05102481.8 2005-03-30
PCT/EP2006/061152 WO2006103261A2 (en) 2005-03-30 2006-03-29 Inhibitors of neurotrypsin and determination thereof

Publications (2)

Publication Number Publication Date
CN101193858A CN101193858A (zh) 2008-06-04
CN101193858B true CN101193858B (zh) 2012-01-04

Family

ID=34939082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800101171A Expired - Fee Related CN101193858B (zh) 2005-03-30 2006-03-29 神经蛋白酶抑制剂及其确定

Country Status (15)

Country Link
US (1) US7897364B2 (https=)
EP (1) EP1868989A2 (https=)
JP (1) JP4920675B2 (https=)
KR (1) KR20070116932A (https=)
CN (1) CN101193858B (https=)
AU (1) AU2006228150B2 (https=)
BR (1) BRPI0609654A2 (https=)
CA (1) CA2600791A1 (https=)
IL (1) IL186120A (https=)
MX (1) MX2007011961A (https=)
NO (1) NO20075461L (https=)
NZ (1) NZ562796A (https=)
RU (1) RU2424228C2 (https=)
WO (1) WO2006103261A2 (https=)
ZA (1) ZA200707359B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases
PL1990420T3 (pl) * 2007-05-10 2011-01-31 Neurotune Ag Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
EP2635559A2 (en) 2010-11-01 2013-09-11 Neurotune AG Neurotrypsin inhibitors
WO2012059443A2 (en) 2010-11-01 2012-05-10 Neurotune Ag Novel neurotrypsin inhibitors
EP2631657A1 (en) * 2012-02-25 2013-08-28 Neurotune AG Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783949B1 (en) * 1999-04-30 2004-08-31 Aventis Pharma Deutschland Gmbh Processes for determining whether a test substance contains lipases or lipase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
DE10247478A1 (de) * 2002-10-11 2004-06-24 Bioagency Ag Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783949B1 (en) * 1999-04-30 2004-08-31 Aventis Pharma Deutschland Gmbh Processes for determining whether a test substance contains lipases or lipase inhibitors

Also Published As

Publication number Publication date
JP4920675B2 (ja) 2012-04-18
EP1868989A2 (en) 2007-12-26
KR20070116932A (ko) 2007-12-11
WO2006103261A9 (en) 2010-05-27
CN101193858A (zh) 2008-06-04
CA2600791A1 (en) 2006-10-05
JP2008538178A (ja) 2008-10-16
RU2424228C2 (ru) 2011-07-20
WO2006103261A3 (en) 2007-02-22
IL186120A (en) 2012-08-30
AU2006228150A1 (en) 2006-10-05
RU2007139754A (ru) 2009-05-10
WO2006103261A2 (en) 2006-10-05
AU2006228150B2 (en) 2011-09-29
US7897364B2 (en) 2011-03-01
US20090170950A1 (en) 2009-07-02
ZA200707359B (en) 2009-08-26
IL186120A0 (en) 2008-01-20
NO20075461L (no) 2007-11-20
BRPI0609654A2 (pt) 2010-04-20
MX2007011961A (es) 2008-03-14
NZ562796A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
Bravo et al. Accurate and efficient cleavage of the human insulin proreceptor by the human proprotein-processing protease furin. Characterization and kinetic parameters using the purified, secreted soluble protease expressed by a recombinant baculovirus.
US7070977B2 (en) Human serine protease D-G polypeptide
JPH022372A (ja) 活性化されたヒトプロテインｃの直接発現のためのベクターおよび化合物
Brakch et al. Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations
Côté et al. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A)
Böhm et al. Up‐regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage
US20030108998A1 (en) Aggrecan degrading metallo proteases
US6322962B1 (en) Sterol-regulated Site-1 protease and assays of modulators thereof
IL186120A (en) Method for determining whether a test compound is an inhibitor of neurotrypsin
Zhang et al. The expression of novel membrane-type matrix metalloproteinase isoforms is required for normal development of zebrafish embryos
US20020090373A1 (en) ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
JPH11513892A (ja) 組換え血液凝固プロテアーゼ
AU630879B2 (en) A tissue plasminogen activator analogue
JP2004520850A (ja) 生体試料のカルパイン３活性を検出する方法、および前記方法を実施するためのペプチド
US20090017042A1 (en) Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) [af217798]
USH1973H1 (en) Human neutrophil collagenase splice variant
US20080199447A1 (en) Catalytic domain of adam33 and methods of use thereof
US6458552B1 (en) Metalloprotease peptide substrates and methods
HK1119156A (en) Inhibitors of neurotrypsin and determination thereof
Wu et al. Purification and characterization of recombinant human renin for X-ray crystallization studies
Fraser Structure, function, and inhibition of type 2 transmembrane serine proteases
CA2562683A1 (en) Adamts-8 proteins and uses thereof
US20040014636A1 (en) Pharmaceutical compositions comprising a modulator of adamts-1
Williamson A comparative analysis of the FIXa active site using Kunitz-type inhibitors
JPH09135684A (ja) ヒト膵型アミラーゼの製造法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119156

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120104

Termination date: 20130329

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1119156

Country of ref document: HK